Results 11 to 20 of about 1,214 (169)

Beyond the libretto

Stridon, 2021
Nowadays both intra- and interlingual surtitles are an inherent element of almost all opera produc­tions and, partly thanks to this technology, opera is now going through a renaissance.
Aleksandra Ożarowska
doaj   +2 more sources

First-line Selpercatinib or Chemotherapy and Pembrolizumab in Patients From East Asia With RET Fusion–Positive NSCLC: A LIBRETTO-431 Subgroup Analysis [PDF]

JTO Clinical and Research Reports
Introduction: Selpercatinib’s consistent efficacy and manageable safety profile were observed in patients with RET fusion–positive NSCLC across geographies in single-arm studies (LIBRETTO-001 and LIBRETTO-321).
Koichi Goto, MD, PhD, Herbert H. Loong, M.B.B.S., Caicun Zhou, MD, PhD, Kazumi Nishino, MD, PhD, Dae Ho Lee, MD, PhD, Se-Hoon Lee, MD, James Chih-Hsin Yang, MD, PhD, Dan Liu, PhD, Minji Kim Uh, PhD, Hongmei Han, MS, MAS, Tarun Puri, MD, Aimee Bence Lin, PhD, Ying Cheng, MD   +12 more
doaj   +2 more sources

Population Pharmacokinetics Modeling of Selpercatinib to Support Posology in Pediatric Patients With RET-Altered Metastatic Thyroid Cancer or Solid Tumors. [PDF]

CPT Pharmacometrics Syst Pharmacol
ABSTRACT Selpercatinib is a first‐in‐class, highly selective, RET kinase inhibitor with CNS activity, approved for the treatment of RET‐altered lung, thyroid, and other cancers. We report pharmacokinetic analyses to identify factors affecting selpercatinib steady‐state exposure and support posology in pediatric patients.
Liu D, van der Walt JS.
europepmc   +2 more sources

Patient‐Reported Outcomes with Selpercatinib Among Patients with RET Fusion–Positive Non‐Small Cell Lung Cancer in the Phase I/II LIBRETTO‐001 Trial

The Oncologist, EarlyView., 2021
Abstract Background LIBRETTO‐001 is an ongoing, global, open‐label, phase I/II study of selpercatinib in patients with advanced or metastatic solid tumors. We report interim patient‐reported outcomes in patients with RET fusion–positive non‐small cell lung cancer (NSCLC).
Anna Minchom, Aaron C. Tan, Erminia Massarelli, Vivek Subbiah, Valentina Boni, Bruce Robinson, Lori J. Wirth, Lisa M. Hess, Min‐Hua Jen, Jennifer Kherani, Elizabeth Olek, Caroline E. McCoach   +11 more
wiley   +1 more source

Patient‐Reported Outcomes with Selpercatinib Treatment Among Patients with RET‐Mutant Medullary Thyroid Cancer in the Phase I/II LIBRETTO‐001 Trial

The Oncologist, EarlyView., 2021
Abstract Background Medullary thyroid cancer (MTC) standard of care includes multikinase inhibitors (MKIs), which can exacerbate disease‐related diarrhea, primarily because of non‐RET kinase inhibition. We report diarrhea and other patient‐reported outcomes (PROs) with selpercatinib, a highly selective RET inhibitor, among patients with RET‐mutant MTC ...
Lori J. Wirth, Bruce Robinson, Valentina Boni, Daniel S.W. Tan, Caroline McCoach, Erminia Massarelli, Lisa M. Hess, Min‐Hua Jen, Jennifer Kherani, Elizabeth Olek, Vivek Subbiah   +10 more
wiley   +1 more source

A Case of Syndrome of Inappropriate Secretion of Antidiuretic Hormone Induced by Selpercatinib in a Patient With RET Fusion Gene-Positive Non-Small Cell Lung Cancer. [PDF]

Respirol Case Rep
We report a case of selpercatinib‐induced syndrome of inappropriate secretion of antidiuretic hormone (SIADH) that improved after drug withdrawal and was safely resumed at a reduced dose. ABSTRACT An 80‐year‐old woman with a lung nodule in the right lower lobe and pleural thickening was diagnosed with lung adenocarcinoma by a surgical lung biopsy.
Tanaka Y, Ikegami N, Miyamoto K, Shingu Y, Okagaki N, Sakamoto H, Nakanishi T, Nakamura S, Matsumura K, Ueyama M, Kaji Y, Hashimoto S, Tanaka E, Taguchi Y, Ohsumi Y, Nakagawa T, Matsunaga S, Hajiro T.   +17 more
europepmc   +2 more sources

The evolution of RET inhibitor resistance in RET-driven lung and thyroid cancers

Nature Communications, 2022
The results of the phase 1/2 LIBRETTO-001 clinical trial has recently established the efficacy of the RET inhibitor selpercatinib in RET-driven cancers.
Ezra Y. Rosen, Helen H. Won, Youyun Zheng, Emiliano Cocco, Duygu Selcuklu, Yixiao Gong, Noah D. Friedman, Ino de Bruijn, Onur Sumer, Craig M. Bielski, Casey Savin, Caitlin Bourque, Christina Falcon, Nikeysha Clarke, Xiaohong Jing, Fanli Meng, Catherine Zimel, Sophie Shifman, Srusthi Kittane, Fan Wu, Marc Ladanyi, Kevin Ebata, Jennifer Kherani, Barbara J. Brandhuber, James Fagin, Eric J. Sherman, Natasha Rekhtman, Michael F. Berger, Maurizio Scaltriti, David M. Hyman, Barry S. Taylor, Alexander Drilon   +31 more
doaj   +1 more source

Tra drammaturgia e linguistica: analisi di "…tra la Carne e il Cielo" e intervista alla librettista Maddalena Mazzocut-Mis

Itinera, 2020
...tra la Carne e il Cielo is an opera by Azio Corghi set to a libretto by Maddalena Mazzocut-Mis. The inspiration of the opera is the essay Studi sullo stile di Bach by Pier Paolo Pasolini, a critical analysis to Bach’s violin sonatas.
Davide Ciprandi
doaj   +1 more source

Azio Corghi “…tra la Carne e il Cielo” da Pier Paolo Pasolini. Drammaturgia poetica di Maddalena Mazzocut-Mis per Violoncello concertante, Recitante maschile, Soprano, Pianoforte e Orchestra

Itinera, 2020
Here we publish the libretto of Azio Corghi’s Opera Tra la Carne e il Cielo, written by Maddalena Mazzocut-Mis. The libretto assembles and transforms different passages from Pier Paolo Pasolini’s texts in order to investigate the relationship within ...
Maddalena Mazzocut-Mis
doaj   +1 more source

TRANSLATION TRANSFORMATIONS OF THE LIBRETTO BY N. TATE FOR THE OPERA “DIDO AND AENEAS”

Sovremennye Issledovaniâ Socialʹnyh Problem, 2022
The article is devoted to the analysis of translation transformations in musical compositions. Studies in the field of musical translation and opera compositions were considered, difficulties that an interpreter may face were identified.
Daniela V. Ustinova, Natalia V. Lashtabova   +1 more
doaj   +1 more source